ICYMI: 2021 Rheumatology Year in Review

Save

For 2022, let's look our top 10 list of advances, game-changers, worries and those better medical practices that evolved during 2021.

What Worries You, Masters You (7.1.2022)

Save

Dr. Jack Cush reviews recent news, regulatory and guideline updates from the past week on RheumNow.com.  Studies on methotrexate use, COVID vaccination, Supplements and vitamins, and arthrocentesis despite anticoagulation are discussed.

New Updated GRAPPA Psoriatic Arthritis Recommendations

Save

The GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis) treatment recommendations have been updated and the 2021 evidence-based guidance is rich in treatment recommendations based on the key disease "domains" - peripheral arthritis, axial disease, enthesitis, dactylitis, skin and nail psoriasis; with new PsA related domains uveitis and inflammatory bowel disease.

Two Week Twitter (6.17.2022)

Save

Dr. Jack Cush does a 2-week review of RheumNow Tweets on news and journal citations worth noting, along with some opinions on Telehealth, manpower, monkeypox and the price of drugs.

Not All RA Drug Classes Are Created Equal

Save

Clear differences were apparent among the three major types of targeted medications for rheumatoid arthritis (RA) in a large European registry study.

JAK/STAT pathway in pyoderma gangrenosum: a new therapeutic highway?

Save

Pyoderma gangrenosum (PG) is rare, but often associated with different forms of arthritis, in particular rheumatoid arthritis and inflammatory bowel diseases. 

Flares Not Increased Following Recombinant Zoster Vaccine Injections

Save

Insurance claims analysis has shown that the use of the (CDC recommended) recombinant zoster vaccine (RZV) for prevention of herpes zoster was highly used in patients with immune-mediated inflammatory diseases and was safe, as higher rates of arthritis flares were not evident.

Spondyloarthritis and COVID-19

Save

There are still questions surrounding COVID-19, and some common questions I receive from patients revolve around what to do with their current DMARDs or should they even start treatment during this pandemic. Two studies focused on this question. 

ACR Applauds FTC Decision to Investigate PBM's

Save

The American College of Rheumatology applauds the Federal Trade Commission’s decision to investigate the business practices of pharmacy benefit managers (PBMs), which continue to increase PBM profit margins while placing the burden of skyrocketing drug costs on America’s most vulnerable patients,

JAK/STAT pathway in pyoderma gangrenosum: a new therapeutic highway? Pyoderma gangrenosum (PG) is rare, but often associated with different forms of arthritis, in particular rheumatoid arthritis and inflammatory bowel diseases. https://t.co/SvkcZwqzBo https://t.co/M3BkoF4amb